Allergy Therapeutics plc (LON:AGY – Get Free Report)’s stock price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 8.73 and traded as low as GBX 5.20. Allergy Therapeutics shares last traded at GBX 5.70, with a volume of 621,223 shares changing hands.
Allergy Therapeutics Stock Performance
The firm has a market cap of £360.95 million, a price-to-earnings ratio of -5.88, a PEG ratio of -30.70 and a beta of 0.83. The company has a 50-day moving average price of GBX 6.09 and a 200 day moving average price of GBX 8.71. The company has a quick ratio of 1.48, a current ratio of 1.13 and a debt-to-equity ratio of 629.58.
Allergy Therapeutics Company Profile
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
See Also
- Five stocks we like better than Allergy Therapeutics
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
